CJC-1295 Buyer's Guide: 4 Decisions Before You Buy
Your pituitary gland does not release growth hormone in a steady stream. It releases it in pulses, sharp spikes that happen mostly at night during deep sleep, and those spikes matter because the pituitary and the receptors downstream are designed to respond to contrast, not to a constant signal. That architecture is the reason secretagogues became interesting in the first place.
The basic chain works like this. Your hypothalamus releases something called growth hormone releasing hormone, which is the signal your pituitary is waiting for. When the pituitary gets that signal, it releases a burst of growth hormone into circulation. Growth hormone then travels to the liver, where it stimulates production of something called IGF-1, which is insulin-like growth factor 1, and IGF-1 is what actually drives most of the tissue-level effects people associate with growth hormone. The whole system has a natural brake built in too, a hormone called somatostatin, which the hypothalamus releases to suppress the pituitary and end each pulse. The result is a rhythm, peaks and valleys, not a flat line.
CJC-1295 without DAC is a synthetic version of growth hormone releasing hormone. It mimics the signal your hypothalamus would send, which means it plugs into a system that already knows what to do with it rather than bypassing it entirely.
The first decision most buyers get wrong is the DAC question.
DAC stands for drug affinity complex, and it is a chemical modification that lets CJC-1295 bind to albumin, a protein that circulates in your blood and acts like a slow-release carrier. The binding extends the half-life from roughly 30 minutes up to about seven days, which means one or two injections per week instead of daily or three-times-weekly injections. On paper that sounds like a convenience upgrade.
The problem is what that extended half-life actually does to the system. Instead of sending a sharp pulse of GHRH signal and then clearing out so somatostatin can do its job and reset the rhythm, DAC version stays elevated for days at a time. You get a flat, sustained elevation of GHRH signaling rather than the pulsatile pattern the pituitary evolved to respond to. And if the goal is flat, sustained growth hormone elevation, exogenous growth hormone achieves that more reliably, with a pharmacology that has been studied in clinical settings for decades. The entire rationale for using a secretagogue is that it works within the pulse architecture, and DAC removes that architecture. No DAC is the only version that preserves the mechanism you are actually paying for.
The second decision is whether to buy a blend or separate vials of CJC-1295 and Ipamorelin, which are almost always used together.
Ipamorelin works through a completely different receptor than CJC-1295. CJC binds to the GHRH receptor on pituitary cells and tells them to release growth hormone. Ipamorelin binds to something called the ghrelin receptor, technically GHSR1a, which is a separate trigger that amplifies the pituitary's response and also suppresses somatostatin activity, meaning it reduces the brake while CJC is pressing the accelerator. The two signals together produce a larger GH pulse than either alone, which is why the combination became standard.
Blends work fine, but you need to keep the math clear. Five milligrams of CJC and five milligrams of Ipamorelin combined in two milliliters of bacteriostatic water gives you a concentration of 2.5 milligrams per milliliter for each compound. At that concentration, 10 units on an insulin syringe delivers 250 micrograms of each. Knowing that math matters because dosing errors compound over weeks and months.
The third decision is cycling, and this is where most of the confusion lives.
The common assumption is that you cycle CJC and Ipamorelin together because both compounds desensitize their receptors over time. That is not quite right. The GHRH receptor that CJC works through does not appear to desensitize meaningfully with continuous use. Tesamorelin, which is a stabilized GHRH analog approved by the FDA, was dosed continuously for 52 weeks in clinical trials and IGF-1 levels held at week-26 levels all the way through week 52 without any attenuation. The CJC side of the equation is not the reason you cycle.
The ghrelin receptor that Ipamorelin works through is a different story. Research into GHSR1a desensitization has shown that sustained agonist stimulation drives something called beta-arrestin recruitment, which is a cellular mechanism where the receptor gets pulled off the cell surface and internalized, reducing the number of active receptors available to respond. Fewer receptors means a blunted signal even at the same dose. In practical terms, after roughly 12 to 16 weeks of continuous use, IGF-1 levels can fall 20 to 30 percent from their peak response even though the dose has not changed. That is the receptor population shrinking, not the compound losing potency.
This is why the standard protocol is three months on, one month off. The off period allows receptor populations to recover and re-sensitize so the next cycle starts from a full receptor density again. The CJC component would not require this break on its own. The cycling exists because of the Ipamorelin.
The fourth decision is recognizing when secretagogues are no longer the right tool.
Secretagogues work within your biological ceiling. They make your pituitary produce more growth hormone than it would on its own, but they cannot push past the maximum output your pituitary is physically capable of. If your goal requires GH levels beyond what your own pituitary can generate, the compound category has to change.
The more immediate issue is that you cannot run secretagogues and exogenous growth hormone simultaneously and expect either to function properly. After a single injection of exogenous growth hormone, the resulting increase in circulating GH triggers a somatostatin surge that inhibits the GHRH pathway by 86 percent. That means the CJC you are injecting has almost no functional pathway left to work through. The pituitary is suppressed before the GHRH signal even arrives. The two approaches are not additive, they are mutually exclusive in practice, and running both at once mostly means wasting the secretagogue.
Most people starting out assume the goal is to eventually add growth hormone on top of secretagogues as their protocols get more advanced. The actual decision tree runs in the opposite direction. You use secretagogues to optimize what your own system can produce while keeping the feedback loop intact, and when that ceiling is no longer sufficient for your goals, you exit secretagogues entirely and move to exogenous growth hormone instead.
The feedback loop is not just a nice feature to preserve. It is the mechanism that lets your body regulate itself, detect excess, and respond appropriately. The reason secretagogues became a serious option is precisely that they work through it rather than around it. Understanding where that loop breaks down, and what breaks it, is what separates a protocol that makes sense from one that just sounds like it does.
References
- FDA Prescribing Information. EGRIFTA (tesamorelin). 2025 — 52-week continuous dosing, IGF-1 levels maintained at week-26 levels through week 52
- Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide. Endocrinology. 1984 — GHRP/ghrelin receptor agonist mechanism
- PNAS. Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand. 2022 — β-arrestin mediated GHSR1a desensitization mechanism
- Veldhuis JD et al. Somatostatin inhibition of GHRH-stimulated GH secretion. J Clin Endocrinol Metab — 86% GHRH pathway inhibition after exogenous GH
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin 26-week clinical trial efficacy
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.